8 results
Primary Objective:To evaluate the efficacy and safety of 2 doses of benralizumab in patients with moderate to very severe Chronic Pulmonary Disease (COPD).Secondary Objectives:To evaluate the effect of two doses of benralizumab on:* health status/…
The primary objective is to identify which coagulation factors are associated with unsuccessful reversal of VKA activity. Secondary objectives include the assessment of the number of patients reaching normalized INR (i.e. <1.8) and the number…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatory eosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-head comparison of the presence…
The current trial aims to demonstrate that sugammadex is generally safe and effective for reversing both moderate and deep block after rocuronium or vecuronium induced NMB in term neonates and young children.
To determine the effect of benralizumab on the rate of asthma exacerbationsSubstudy: - To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen whilemaintaining asthma control.- To assess…
The objective of this Phase 3 study is to investigate the safety and efficacy of benralizumab as a treatment for patients with eosinophilic gastritis and/or gastro-enteritis.
To evaluate the effect of benralizumab 100 mg on COPD exacerbations in patients with moderate to very severe COPD.
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…